vialroom

#tirzepatide 2024-11-14

Thursday11 messages4 participantstimes are UTC
Highlights from this day
  • area_percent — dual agonist, GIP as well as GLP-1, thats the whole difference in one line 19:12
  • area_percent — the GIP explanation for easier nausea is plausible and i still treat it as a story not a fact 19:15
  • area_percent — the sweet spot thing is survivorship, the people it worked for stayed and said so 19:29
  • declared_value — SURMOUNT was the weight programme and SURPASS was diabetes, thats the split people mix up 19:36
  • declared_value — i sat at 7.5 for 3 months and never needed more, which is where the folklore comes from 19:39
AP

dual agonist, GIP as well as GLP-1, thats the whole difference in one line

the GIP explanation for easier nausea is plausible and i still treat it as a story not a fact

easier gi for me

same plateau here

wk 1-4    2.5mg
wk 5-8    5.0mg
wk 9-20   7.5mg   <- stayed here
wk 21-24  10.0mg  (no extra benefit for me)
wk 25+    7.5mg   (came back down)
🤝12
MM

no clean conversion

janoshik-sg-1177.pdf
2 pages · 119 KB · not retained in the public archive

the sweet spot thing is survivorship, the people it worked for stayed and said so

📈1⚠️5

switched last year

DV

SURMOUNT was the weight programme and SURPASS was diabetes, thats the split people mix up

Cited study
Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4)
JAMA · 2024
Randomised withdrawal after a 36-week lead-in. Pairs with STEP 4.

i sat at 7.5 for 3 months and never needed more, which is where the folklore comes from